pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›TECENTRIQ
drug
save

TECENTRIQ

updated 6mo ago
by Genentech Inc
community read0 votes

🐶 often sniffed alongside

top 8
  • drugatezolizumab178 co-mentions · 46 sources
  • tagApproval176 co-mentions · 44 sources
  • companyGenentech Inc88 co-mentions · 44 sources
  • drugTECENTRIQ HYBREZA20 co-mentions · 5 sources
  • drug(atezolizumab + hyaluronidase (human recombinant))10 co-mentions · 5 sources
  • tagOncology5 co-mentions · 2 sources
  • companyDana-Farber Cancer Institute Inc1 co-mentions · 1 sources
  • tagHepatology1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying TECENTRIQ

  • phase3Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancerrecruitingn=550
  • phase3A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamignot yet recruitingn=68
  • phase2A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)active not recruitingn=99
  • phase1Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCCactive not recruitingn=12
  • phase3A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancercompletedn=620
  • phase2A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosisactive not recruitingn=30
  • phase2A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)recruitingn=170
  • phase3A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Studyrecruitingn=200

News(10)

  • Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
    Roche is paying Zymeworks $55 million upfront for ZW209, bagging global rights to a trispecific designed to improve on the rate and depth of responses achieved by Amgen’s Imdelltra.
    fiercebiotech · 27d ago
  • Roche affirms sales outlook amid doubts about its future
    Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.
    biopharma_dive · 28d ago
  • Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
    Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.
    biospace · 28d ago
  • ESMO: Boehringer builds case for late-phase rival to Amgen’s Imdelltra
    Boehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival to Amgen’s Imdelltra that entered phase 3 this year.
    fiercebiotech · 28d ago
  • BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
    While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analyst…
    biospace · 1mo ago
  • City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut
    Plus news about Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio and Tecentriq. City Therapeutics charts $158M IPO: The RNAi startup from former Alnylam executives is looking t…
    endpoints · 1mo ago
  • Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
    A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.
    biopharma_dive · 1mo ago
  • Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
    MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…
    fiercebiotech · 2mo ago
  • 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
    Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
    biospace · 2mo ago
  • FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer
    The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment of metastatic colorectal cancer.
    fiercebiotech · 2mo ago
view all news mentions →
brand
TECENTRIQ
generic
ATEZOLIZUMAB
Data sources
ClinicalTrials.gov
last refreshed 6h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?